Vaccines in the treatment of invasive candidiasis.
Virulence. 2015 Jan 6;:0
Authors: Wang X, Sui X, Yan L, Wang Y, Cao Y, Jiang Y
Abstract Candida albicans is the most common cause of hematogenously disseminated candidiasis, and this disease is particularly prevalent in immunocompromised patients. The mortality of invasive candidiasis remains 40% to 50% even with the proper treatment with current antifungal drugs. Recently, with the better understanding of host-fungus interactions, notable progress has been made in antifungal vaccine research. Most antifungal vaccines exert protection by inducing either (or both) B-cell and T-cell responses. Here we summarize the current available information on C. albicans vaccines, highlight the obstacles that researchers identified, and offer several suggestions.
PMID: 25559739 [PubMed - as supplied by publisher]